Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine

被引：18
|
作者：
Baldanti, F [1 ]
Paolucci, S
Maga, G
Labo, N
Hübscher, U
Skoblov, AY
Victorova, L
Spadari, S
Minoli, L
Gerna, G
机构：
[1] IRCCS, Policlin San Matteo, Serv Virol, Pavia, Italy
[2] CNR, Ist Genet Mol, Pavia, Italy
[3] Univ Zurich, Inst Vet Biochem & Mol Biol, Zurich, Switzerland
[4] Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow, Russia
[5] Univ Pavia, Ist Clin Malattie Infett, Pavia, Italy
来源：
AIDS | 2003年 / 17卷 / 10期
关键词：
D O I：
10.1097/00002030-200307040-00021
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Stavudine administration did not increase the frequency of Y181I/C reverse transcriptase (RT) mutations in non-nucleoside reverse transcriptase inhibitor (NNRTI)-treated patients. However, recombinant Y181C HIV-1 showed reduced stavudine susceptibility with respect to both recombinant wild-type and K103N HIV-1 strains. In addition, recombinant Y181I RT enzyme showed reduced susceptibility to stavudine with respect to both wild-type and K103N RT. A previously unnoticed role of Y181I/C RT changes selected by nevirapine or other NNRTI in determining stavudine resistance is documented.
引用
收藏
页码：1568 / 1570
页数：3
相关论文
共 50 条
  • [1] No evidence for stavudine resistance due to nevirapine-selected mutation Y181C in HIV-1 reverse transcriptase in a large genotype/phenotype database
    Korn, K
    Schmidt, B
    Walter, H
    ANTIVIRAL THERAPY, 2004, 9 (04) : U47 - U47
  • [2] Nevirapine resistance mutation at codon 181 of the HIV-1 reverse transcriptase confers stavudine resistance by increasing nucleotide substrate discrimination and phosphorolytic activity
    Blanca, G
    Baldanti, F
    Paolucci, S
    Skoblov, AY
    Victorova, L
    Hübscher, U
    Gerna, G
    Spadari, S
    Maga, G
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (18) : 15469 - 15472
  • [3] Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance
    Neogi, Ujjwal
    Shet, Anita
    Shamsundar, Ranjani
    Ekstrand, Maria L.
    AIDS, 2011, 25 (08) : 1123 - 1126
  • [4] The Emerging Profile of Cross-Resistance among the Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors
    Sluis-Cremer, Nicolas
    VIRUSES-BASEL, 2014, 6 (08): : 2960 - 2973
  • [5] Quantum computational analysis for drug resistance of HIV-1 reverse transcriptase to nevirapine through point mutations
    He, X
    Mei, Y
    Xiang, Y
    Zhang, DW
    Zhang, JZH
    PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2005, 61 (02) : 423 - 432
  • [6] Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors
    Harrigan, PR
    Mo, T
    Wynhoven, B
    Hirsch, J
    Brumme, Z
    McKenna, P
    Pattery, T
    Vingerhoets, J
    Bacheler, LT
    AIDS, 2005, 19 (06) : 549 - 554
  • [7] Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase
    Barnard, John P.
    Huber, Kelly D.
    Sluis-Cremer, Nicolas
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (08)
  • [8] In vitro HIV-1 cross-resistance against reverse transcriptase inhibitor-based microbicides
    Selhorst, P.
    Vazquez, A. C.
    Terrazas-Aranda, K.
    Michiels, J.
    Heyndrickx, L.
    Arien, K.
    Quinones-Mateu, M. E.
    Vanham, G.
    ANTIVIRAL THERAPY, 2010, 15 : A141 - A141
  • [9] HIV-1 reverse transcriptase mutations that suppress zidovudine resistance also increase in vitro susceptibility to tenofovir, but not stavudine
    Parkin, NT
    Chappey, C
    Petropoulos, CJ
    Hellmann, N
    ANTIVIRAL THERAPY, 2003, 8 (03) : U41 - U42
  • [10] Competitive capacity of HIV-1 strains carrying M184I or Y181I drug-resistant mutations
    Li Jue
    Li Lin
    Li Han-ping
    Zhuang Dao-min
    Liu Si-yang
    Liu Yong-jian
    Bao Zuo-yi
    Wang Zheng
    Li Jing-yun
    CHINESE MEDICAL JOURNAL, 2009, 122 (09) : 1081 - 1086
12345